SUMMARY Prostaglandin E (PGE2) was infused intravenously to eight women for the termination of pregnancy and tests of platelet function: coagulation and fibrinolysis were studied before and during the infusion.
Prostaglandins have been included among the agents which may depress platelet function and so have a potential in the traatment of thrombotic disorders which may be initiated by platelets adhering to the vessel wall.
Prostaglandins have in vitro a powerful inhibitory effect on platelet adhesiveness and aggregation (Kloeze, 1967; Emmons, Hampton, Harrison, Honour, and Mitchell, 1967; Irion and Blomback, 1969; Weeks, Chandra Sekhar, and Ducharme, 1969; Kinlough-Rathbone, Packham, and Mustard, 1970) . Prostaglandin E1 is the most potent inhibitor of platelet function and PGE2 has about a fifth of its activity (Irion and Blomback, 1969) . Studies in vivo in animals have shown that the intravenous or topical administration of PGE1 can inhibit platelet thrombus formation at the site of vessel injury and prolong bleeding times (Emmons et al, 1967 ; Kinlough-Rathbone et al, 1970) . Such evidence suggested that prostaglandins might have a role in the prevention of thrombosis (Lancet, 1971) .
In contrast to studies in experimental animals, attempts to demonstrate an effect of prostaglandin on platelets in human subjects have been disappointing as the dosage is limited by side effects (Elkeles, Hampton, Harrison, and Mitchell, 1969; Carlsson, Irion, and Orb, 1968) . Although Elkeles et al (1969) (1968) found no change in ADP aggregation in three men receiving PGE1 and Karim and Filshie (1972) found platelet adhesiveness by Hellem's method unaltered by intravenous PGE2.
The use of intravenous PGE2 to induce therapeutic abortion has given us an opportunity to test its effect upon platelet function, coagulation, and fibrinolysis in eight women undergoing termination ofpregnancy.
Patients and Methods
The patients were all healthy women, between the 12th and 20th week of pregnancy, having an intravenous PGE2 infusion for therapeutic abortion. Their ages ranged from 18 to 34 years. An intravenous infusion of normal saline was commenced and a venous blood sample was collated from the opposite arm; 9 ml was mixed with 1 ml of 3.80/ sodium citrate for coagulation and fibrinolytic tests; 2 ml was added to edetic acid for platelet counting and 2 ml was added to a tube containing glass beads and 1 mg of the fibrinolytic inhibitor tranexamic acid for assay of fibrinolytic degradation products (FDP). The coagulation and fibrinolytic assays were performed within 45 minutes of collection of the blood 354
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An intravenous infusion of PGE2 was then given at the rate of 2-5 ,ug/min for the first hour and at 5 ,tg/min thereafter. After three hours of PGE2 infusion, a second blood sample was collected, and platelet function, coagulation, and fibrinolytic tests were repeated. None of the patients had aborted or shown evidence of uterine activity at the time of the second blood sample.
Platelet adhesiveness to a cellophane membrane in a test cell was measured by the method of Lindsay, Prentice, Ferguson, Muir, and McNicol (1973) . In this method, 10 ml of citrated blood is passed over a cellophane membrane and platelet counts are performed on the blood before and after being passed through the cell to calculate the retention of platelets.
Platelet adhesiveness to glass was measured by the method of Hellem (1960) as modified by Hirsh, McBride, and Dacie (1966) ; also platelet aggregation was measured at room temperature by the turbimetric method of Born and Cross (1963) induced by both ADP (0-05 units/ml) and collagen; platelet factor 3 availability was estimated as described by Hassanein et al (1970) ; platelets were counted by the method of Dacie and Lewis (1963) .
The coagulation tests performed were thrombin clotting time (McNicol and Douglas, 1964) , onestage prothrombin time (Douglas, 1962) , kaolin partial thromboplastin time (Proctor and Rapaport, 1961) , recalcification time in plastic (Biggs and Macfarlane, 1962) , factor V (Shanberge, Matsuoka, and Fukui, 1967) , factor VIII (Breckenridge and Ratnoff, 1962) , fibrinogen (Ratnoff and Menzie, 1964) , and plasma antithrombin (Howie, Prentice, and McNicol, 1973) . Tests of fibrinolysis were plasminogen (Remmert and Cohen, 1949) , euglobulin lysis time (Nilsson and Olow, 1962) , urokinase sensitivity test (McNicol, Gale, and Douglas, 1963) , antiplasmin (Howie, Mallinson, Prentice, Home, and McNicol, 1970) , and serum FDP (Bonnar Davidson, Pidgeon, McNicol, and Douglas, 1969) .
In respect of the ADP-induced platelet aggregation, a further five women were studied; this was done to see if there was a different response to ADP in those women who successfully aborted following infusion as compared with those in whom the PGE2 failed to induce uterine activity.
Results
PLATELET ADHESIVENESS (FIG 1) Some patients demonstrated the effect of rapid platelet disaggregation more strikingly than others. The patients in whom intravenous PGE2 successfully went on to induce abortion were compared with those in whom the PGE2 failed (fig 3) . Considering only the five cases in whom the PGE2 failed to induce abortion, the PGE2 infusion induced no change in either ADP-induced platelet aggregation or disaggregation. In contrast, in the eight patients in whom the intravenous PGE2 caused successful abortion, the rate of platelet disaggregation was increased during the PGE2 infusion as compared with the pre-infusion results in all cases (p < 0 01). 
EUGLOBULIN LYSIS ACTIVITY
There was a significant rise in mean euglobulin lysis activity from 1 1 units before PGE2 infusion to 2-3 units during the infusion (p < 0 05).
OTHER TESTS OF PLATELET FUNCTION, COAGULATION, AND FIBRINOLYSIS
In eight patients before and during PGE2 infusion the mean platelet count fell from 246 000/cmm to 242 000/cmm, the maximum collagen-induced platelet aggregation rose from 53 to 58 %, and mean platelet factor 3 availability fell from 19-6 to 19 3 seconds. None of these changes were significant. None of the other tests of coagulation or fibrinolysis altered significantly during the PGE2 infusion.
SIDE EFFECTS OF PGE2
A few patients experienced minor side effects but none of sufficient severity to stop the treatment.
Discussion
The finding that intravenous PGE2 inhibits platelet adhesiveness to cellophane membranes indicates that PGE2 is capable of influencing platelet function in vivo, in man, and is in keeping with the reports of several animal studies. Emmons et al (1967) showed that PGE1 inhibited white thrombus formation in rabbits. Kinlough-Rathbone et al (1970) confirmed this and demonstrated that PGE1 also prolonged Effect of intravenous prostaglandin E2 on platelet function, coagulation, andfibrinolysis bleeding times and inhibited clot formation at the ends of transected vessels. In rats, PGE1 inhibited platelet aggregation when given in large doses (Chandra Sekhar, 1967) and a continuous PGE, infusion reduced the thrombocytopenia and raised the LD 50 following intravenous ADP injections (Kloeze, 1970a) .
In the human subject the effect of prostaglandins on platelets has been less clear cut. Elkeles et al (1969) showed that platelet electrophoretic mobility in response to ADP was abolished for up to 30 minutes after cessation of a PGE1 infusion. Their main problem was that the prostaglandin caused side effects of flushing and constricting pains in the chest, a problem that was not encountered with PGE2 in this study. On the other hand Karim and Filshie (1972) , using Hellem's method, found no change in platelet adhesiveness during PGE2 infusion, a finding that we confirm in this report. Elkeles et al (1969) used Payling Wright's rotating bulb method and, although they found diminished platelet adhesiveness in four out of eight patients given PGE1, the effect was not significant.
The difference in platelet adhesiveness to glass beads and to a cellophane membrane is of interest. The glass bead column method of testing platelet adhesiveness is related to the release ofADP and other substances from red cells which have been disrupted. In contrast, retention of platelets in the membrane test cell is apparently independent of haematocrit or exogenous ADP release (Lindsay et al, 1973) . Since PGE2 may exert its effect on platelets by inhibiting ADP release, the glass bead method may swamp the effect of PGE2 on platelets by releasing large amounts of aggregating substances from the red cells. It would appear that, in this situation, the membrane test cell provides a more sensitive index of platelet behaviour than the glass bead technique, and may be useful in the future for the assessment of other antiplatelet drugs.
The normal platelet ADP aggregation during PGE2 infusion was in keeping with the findings of Carlsson et al (1968) The mechanism of platelet inhibition by prostaglandins is not clear although evidence is accumulating that they may stimulate cyclic AMP formation and inhibit the release of ADP and calcium ions from the platelets Vigdahl, Marquis, and Tavormina, 1969; Wolfe and Shulman, 1970; Haslam and Lynham, 1972) .
The reason for the rise in antithrombin activity during prostaglandin infusion is uncertain, although it is possible that a rise in antithrombin activity could contribute to an anticoagulant action of prostaglandin. Kloeze (1970b) reported that prostaglandin reduced the strength of clot formation and our finding of raised antithrombin activity could contribute to such an effect. The increase in euglobulin lysis activity was the only evidence that prostaglandin enhanced fibrinolytic activity; euglobulin lysis activity can be raised by non-specific factors such as stress or excitement which may have been responsible for the increased activity, although the prostaglandin itself could have had a direct effect on fibrinolysis.
Studies in vitro have shown that prostaglandins can also inhibit clot retraction (Murer, 1971) , clot tensile strength (Kloeze, 1970b) , and platelet aggregation induced by thrombin, collagen, noradrenaline, and serotonin (Emmons et al, 1967) . However, the concentration of PG used in these experiments far exceeded the dosage which could be given to patients.
Our studies lend support to the evidence from animal studies in vivo that a continuous intravenous infusion of prostaglandin can influence platelet function and might have potential clinical benefit in conditions where platelet-initiated thrombosis is the major problem. However, the hypothesis that a reduction in platelet stickiness may cause therapeutic benefits is still not proved, and it would be important to mount controlled clinical trials to demonstrate the usefulness in the treatment of thrombosis.
